NCT03492918: Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing (‘MUTATION2’)

NCT03492918
Breast Cancer Type: HER2+, HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous system (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03492918

Comments are closed.

Up ↑